Research Analysts’ Updated EPS Estimates for December, 4th (AVGO, CBTX, CLI, DDR, DLPH, FBNC, FMC, FPI, IAG, MCB)

Research Analysts’ updated eps estimates for Monday, December 4th:

Broadcom (NASDAQ:AVGO) had its overweight rating reiterated by analysts at KeyCorp. They currently have a $320.00 target price on the stock, up from their previous target price of $290.00.

Stephens started coverage on shares of CBTX (NASDAQ:CBTX). The firm issued an overweight rating on the stock.

Mack-Cali Realty (NYSE:CLI) was downgraded by analysts at Evercore ISI to an outperform rating.

DDR (NYSE:DDR) was downgraded by analysts at Evercore ISI to an outperform rating.

Royal Bank Of Canada began coverage on shares of Delphi Automotive (NYSE:DLPH). Royal Bank Of Canada issued an outperform rating and a $60.00 price target on the stock.

Stephens initiated coverage on shares of First Bancorp (NASDAQ:FBNC). Stephens issued an equal weight rating on the stock.

FMC (NYSE:FMC) had its neutral rating reaffirmed by analysts at Goldman Sachs Group Inc. They currently have a $98.00 target price on the stock.

Farmland Partners (NYSE:FPI) had its hold rating reaffirmed by analysts at Raymond James Financial, Inc..

International Consolidated Airlns Grp (LON:IAG) had its neutral rating reissued by analysts at Morgan Stanley.

Piper Jaffray Companies started coverage on shares of Metropolitan Bank (NYSE:MCB). They issued a neutral rating and a $46.00 target price on the stock.

Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Momenta’s third-quarter results were overshadowed by the disappointing results from a phase I study on the proposed biosimilar verison of Orencia. Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics, safety and immunogenicity of M834 to Orencia in normal healthy volunteers. Earlier, Momenta suffered a blow when the FDA approved Mylan’s generic version of Copaxone 40 mg. On the other hand, Momenta’s ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months.”

DA Davidson began coverage on shares of Meridian Bank (NASDAQ:MRBK). The firm issued a buy rating and a $22.00 price target on the stock.

Pioneer Natural Resources (NYSE:PXD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Pioneer remains focused on the Permian Basin, which is among the lucrative oil shale plays with less risk for operation. The region has been growing production even with reduced investment. Pioneer has strong earnings surprise history as reflected that the company managed to beat the Zacks Consensus Estimate in all the prior four quarters with an average positive surprise of 67.6%. Moreover, we appreciate the excellent financial health of the company. Pioneer Natural has debt to capitalization ratio of 21.2% which is much lower than 49.7% for the broader industry. However, we are concerned about the company’s expectation of higher exploration expenses during fourth-quarter 2017. Also, over the prior six months, the upstream energy player fell 5%, significantly underperforming the industry’s 6.6% gain.        “

Red Hat (NYSE:RHT) had its overweight rating reissued by analysts at KeyCorp. They currently have a $135.00 price target on the stock, up from their previous price target of $125.00.

Synopsys (NASDAQ:SNPS) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Synopsys is a vendor of electronic design automation (EDA) software to the semiconductor and electronics industries. Though the company’s 4Q17 top and bottom lines both came ahead of the respective estimates and marked year-over-year improvement as well, its escalating costs and expenses, which are thwarting margins, make us increasingly cautious about its near-term profitability. Moreover, its non-GAAP earnings projection for FY18 was also disappointing as it fell short of the Zacks Consensus Estimate. Furthermore, competition from peers, a challenging technology-spending environment and uncertainty surrounding the exact time of realizing acquisition synergies keep us cautious. Nonetheless, we believe the company’s continued focus on rolling out products, acquisitions and deal wins will boost results over the long run. Shares of Synopsys have outperformed the industry in the YTD period.”

Time (NYSE:TIME) had its neutral rating reaffirmed by analysts at Citigroup Inc..

Thermo Fisher Scientific (NYSE:TMO) had its outperform rating reiterated by analysts at Leerink Swann. They currently have a $200.00 target price on the stock, down from their previous target price of $216.00.

Vornado Realty Trust (NYSE:VNO) was downgraded by analysts at Evercore ISI to an outperform rating.

Vantiv (NYSE:VNTV) had its overweight rating reiterated by analysts at KeyCorp. The firm currently has a $85.00 price target on the stock, up from their previous price target of $80.00.

Ventas (NYSE:VTR) had its underperform rating reissued by analysts at Raymond James Financial, Inc..

What are top analysts saying about Broadcom Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Broadcom Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit